HUYA Bioscience Int’l Announces Clinical Trial Milestones In China For Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model

San Francisco, CA, USA, IBC Conference – March 3, 2008 — HUYA Biosciences International (HUYA), the leader in U.S./China pharmaceutical co-development, today announced the completion of three Phase I clinical trial protocols in China of a promising anti-arrhythmic compound, HBI-3000 (Sulcardine sulphate). The data from the trials support a desirable safety profile at dose levels displaying indications of pharmacologic activity. HBI-3000 is being developed as a potential treatment for both atrial and ventricular arrhythmias. Read more